Nymox Pharmaceutical Corporation  

(Public, NASDAQ:NYMX)   Watch this stock  
Find more results for PAUL MCDONALD, ESQ�
2.62
-0.10 (-3.68%)
Jul 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.52 - 2.84
52 week 0.33 - 5.75
Open 2.61
Vol / Avg. 2.60M/1.42M
Mkt cap 101.15M
P/E     -
Div/yield     -
EPS -0.02
Shares 37.19M
Beta 1.46
Inst. own 6%
May 15, 2015
Q1 2015 Nymox Pharmaceutical Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 61.01% -155.76%
Operating margin 63.05% -160.19%
EBITD margin - -159.96%
Return on average assets 559.93% -384.61%
Return on average equity - -
Employees 24 -
CDP Score - -

Address

9900 Cavendish Blvd. Suite 306
ST-LAURENT, QC H4M 2V2
Canada
+1-800-9369669 (Phone)
+1-514-3322227 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Nymox Pharmaceutical Corporation is a Canada-based biopharmaceutical company. The Company focuses on developing NX-1207, a treatment for benign prostatic hyperplasia (BPH) which is in Phase III trials in the United States. The Company has research and development (R&D) pipeline of products in development for the treatment of conditions and diseases such as enlarged prostate (benign prostatic hyperplasia (BPH)), Alzheimer’s disease (AD), E. coli O157:H7 contamination of food and drink products, and bacterial infections and for the diagnosis of AD and other indications. Nymox has a number of diagnostic markers and technologies, including a patented platform for point-of-care testing, and has tests utilizing these technologies in the early stages of development. Nymox also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer’s disease. Nymox has two subsidiaries: Nymox Corporation and Serex, Inc.

Officers and directors

Paul Averback M.D. Chairman of the Board, President, Chief Executive Officer
Age: 64
Bio & Compensation  - Reuters
Erik Danielsen Chief Financial Officer
Age: 52
Bio & Compensation  - Reuters
Jack Gemmell Chief Information Officer, General Counsel, Director
Age: 63
Bio & Compensation  - Reuters
Brian Doyle Senior Manager - Global Sales and Marketing
Age: 60
Bio & Compensation  - Reuters
Roger Guy M.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Randall Lanham Esq. Independent Director
Age: 51
Bio & Compensation  - Reuters
Paul F. McDonald Independent Director
Age: 89
Bio & Compensation  - Reuters
David Morse Ph.D. Independent Director
Age: 58
Bio & Compensation  - Reuters